Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
Express Scripts

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,352,803

« Back to Dashboard

Summary for Patent: 4,352,803

Title: Novel naphthyridine derivatives, intermediates thereof, processes for preparation thereof, and use thereof
Abstract:This invention relates to 1,8-naphthyridine compounds of the formula ##STR1## wherein X is a halogen atom especially fluorine atom, R.sub.1 is an ethyl group or a vinyl group, and R.sub.2 is a hydrogen atom or a lower alkyl group, their salts and processes for the preparation of them. The 1,8-naphthyridine compounds and their salts are useful as antibacterial agents and intermediates thereof.
Inventor(s): Matsumoto; Jun-ichi (Takatsuki, JP), Takase; Yoshiyuki (Amagasaki, JP), Nishimura; Yoshiro (Neyagawa, JP)
Assignee: Dainippon Pharmaceutical Co., Ltd. (Osaka, JP) Laboratoire Roger Bellon (Neuilly sur Seine, FR)
Application Number:06/264,824
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,352,803

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan53/104235Aug 25, 1978
Japan53/157939Dec 20, 1978
Japan53/162095Dec 29, 1978

International Patent Family for Patent: 4,352,803

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina223983► Subscribe
Argentina225195► Subscribe
Argentina227529► Subscribe
Australia5004979► Subscribe
Australia530052► Subscribe
Canada1168241► Subscribe
Czechoslovakia235502► Subscribe
Czechoslovakia235545► Subscribe
Czechoslovakia235546► Subscribe
German Democratic Republic145753► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Cantor Fitzgerald
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: